Please ensure Javascript is enabled for purposes of website accessibility

Why Clovis Oncology's Shares Were Decimated

By Sean Williams - Nov 13, 2012 at 7:20AM

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More

Is this meaningful or just another movement?

Although we don't believe in timing the market or panicking over market movements, we do like to keep an eye on big changes -- just in case they're material to our investing thesis.

What: Shares of oncology-focused biopharmaceutical company Clovis Oncology (CLVS -6.26%) were hammered on Monday, falling nearly 42%, following the release of disappointing clinical data for the company's metastatic pancreatic cancer drug, CO-101.

So what: Details of the LEAP trial were released this morning, showing that Clovis' CO-101 had no difference in overall survival when compared to the current standard of treatment, Gemzar, made by Eli Lilly (LLY 0.46%). Both drugs boasted a median survival rate of six months, and, according to its CEO, Patrick Mahaffy during a conference call following the news release (and via Reuters), the results were "even more ambiguous than we could have imagined." Subsequently, Clovis has halted development of CO-101 and will instead focus on CO-1686, its early stage experimental lung cancer treatment, which should have data out in the first half of 2013.

Now what: If that wasn't enough of a kick in the pants, after the bell on Friday, Celgene (CELG) released its earnings results along with a study showing that its cancer blockbuster Abraxane, when combined with Lilly's Gemzar, improved survival rates in patients with pancreatic cancer. Clovis does have one thing going for it: $6.78 in cash per share with no debt; however, even that balance is slowly dwindling because of clinical trial expenses. For now, I'm perfectly happy keeping my distance from Clovis following today's train wreck.

Craving more input? Start by adding Clovis Oncology to your free and personalized watchlist so you can keep up on the latest news with the company.

Invest Smarter with The Motley Fool

Join Over 1 Million Premium Members Receiving…

  • New Stock Picks Each Month
  • Detailed Analysis of Companies
  • Model Portfolios
  • Live Streaming During Market Hours
  • And Much More
Get Started Now

Stocks Mentioned

Eli Lilly and Company Stock Quote
Eli Lilly and Company
LLY
$304.00 (0.46%) $1.40
Celgene Corporation Stock Quote
Celgene Corporation
CELG
Clovis Oncology, Inc. Stock Quote
Clovis Oncology, Inc.
CLVS
$0.64 (-6.26%) $0.04

*Average returns of all recommendations since inception. Cost basis and return based on previous market day close.

Related Articles

Motley Fool Returns

Motley Fool Stock Advisor

Market-beating stocks from our award-winning service.

Stock Advisor Returns
334%
 
S&P 500 Returns
117%

Calculated by average return of all stock recommendations since inception of the Stock Advisor service in February of 2002. Returns as of 05/24/2022.

Discounted offers are only available to new members. Stock Advisor list price is $199 per year.

Premium Investing Services

Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.